A Systematic Review and Meta-Analysis on Catastrophic Cost incurred by Tuberculosis Patients and their Households

Abstract

Background: As one of the World Health Organization (WHO) End Tuberculosis (TB) Strategy is to reduce the proportion of TB affected families that face catastrophic costs to 0% by 2020. This systematic review and meta-analysis aimed to estimate the pooled proportion of TB affected households who face catastrophic cost. Method: A search of the online database through September 2020 was performed. A total of 5114 articles were found, of which 29 articles got included in quantitative synthesis. Catastrophic cost is defined if total cost related to TB exceeded 20% of annual pre-TB household income. R software was used to estimate the pooled proportion at 95% confidence intervals (CIs) using the fixed/random-effect models. Result: The proportion of patients faced catastrophic cost was 43% (95% CI 34-52, I2= 99%. 32% (95% CI 29 - 35, I2= 70%) among drug sensitive, and 80% (95% CI 74-85, I2=54%) among drug resistant, and 81% (95% CI 78-84%, I2= 0%) among HIV patients. Regarding active versus passive case finding the pooled proportion of catastrophic cost was 12% (95% CI 9-16, I2= 95%) versus 42% (95% CI 35-50, I2= 94%). The pooled proportion of direct cost to the total cost was 45% (95% CI 39-51, I2= 91%). The pooled proportion of patients facing catastrophic health expenditure (CHE) at cut of point of 10% of their yearly income was 45% (95% CI 35-56, I2= 93%) while at 40% of their capacity to pay was 63% (95% CI 40-80, I2= 96%). Conclusion: Despite the ongoing efforts, there is a significant proportion of patients facing catastrophic cost, which represent a main obstacle against TB control.

Perspectives of healthcare and social support sector policymakers on potential solutions to mitigate financial impact among people with TB in Mozambique: a qualitative study

“…A meta-analysis showed that the proportion of costs among people with TB varies according to the type of TB and co-infection with HIV (TB/HIV). This study further showed that the proportion of people facing catastrophic costs at a cut-off point of 20% of their annual income before TB was 43% among people with susceptible TB and 80% among people with drug resistant TB (DR-TB) 9. Financial impact due to TB and DR-TB has been found to be independently associated with adverse TB treatment outcomes (death during treatment, loss to follow-up, treatment failure or recurrent TB disease within 30 months of starting TB treatment) 10 11.…”

“…This study further showed that the proportion of people facing catastrophic costs at a cut-off point of 20% of their annual income before TB was 43% among people with susceptible TB and 80% among people with drug resistant TB (DR-TB). 9 Financial impact due to TB and DR-TB has been found to be independently associated with adverse TB treatment outcomes (death during treatment, loss to follow-up, treatment failure or recurrent TB disease within 30 months of starting TB treatment). 10 11 People from low socioeconomic strata or those with DR-TB are at a particularly high risk of severe financial impact.…”